Lee, Jonathan A. et al. published their research in PLoS One in 2015 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.Formula: C20H15ClN4

Novel phenotypic outcomes identified for a public collection of approved drugs from a publicly accessible panel of assays was written by Lee, Jonathan A.;Shinn, Paul;Jaken, Susan;Oliver, Sarah;Willard, Francis S.;Heidler, Steven;Peery, Robert B.;Oler, Jennifer;Chu, Shaoyou;Southall, Noel;Dexheimer, Thomas S.;Smallwood, Jeffrey;Huang, Ruili;Guha, Rajarshi;Jadhav, Ajit;Cox, Karen;Austin, Christopher P.;Simeonov, Anton;Sittampalam, G. Sitta;Husain, Saba;Franklin, Natalie;Wild, David J.;Yang, Jeremy J.;Sutherland, Jeffrey J.;Thomas, Craig J.. And the article was included in PLoS One in 2015.Formula: C20H15ClN4 This article mentions the following:

Phenotypic assays have a proven track record for generating leads that become first-in-class therapies. Whole cell assays that inform on a phenotype or mechanism also possess great potential in drug repositioning studies by illuminating new activities for the existing pharmacopeia. The National Center for Advancing Translational Sciences (NCATS) pharmaceutical collection (NPC) is the largest reported collection of approved small mol. therapeutics that is available for screening in a high-throughput setting. Via a wide-ranging collaborative effort, this library was analyzed in the Open Innovation Drug Discovery (OIDD) phenotypic assay modules publicly offered by Lilly. The results of these tests are publically available online at www.ncats.nih.gov/expertise/preclin./pd2 and via the PubChem Database (AID 1117321). Phenotypic outcomes for numerous drugs were confirmed, including sulfonylureas as insulin secretagogues and the anti-angiogenesis actions of multikinase inhibitors sorafenib, axitinib and pazopanib. Several novel outcomes were also noted including the Wnt potentiating activities of rotenone and the antifolate class of drugs, and the anti-angiogenic activity of cetaben. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Formula: C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.Formula: C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Maile, Madon M. et al. published their research in Anti-Angiogenesis Drug Discovery and Development in 2014 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Recommanded Product: 212141-54-3

Discovery and development of antiangiogenetic drugs in ovarian cancer was written by Maile, Madon M.;Wong, Evelyn Y. T.;Suzin, Daphne;Birrer, Nicole E.;Penson, Richard T.. And the article was included in Anti-Angiogenesis Drug Discovery and Development in 2014.Recommanded Product: 212141-54-3 This article mentions the following:

It is more than 30 years since the seminal observations by Folkman of the development of new blood vessels (angiogenesis) in tumors. Ovarian cancer remains the most lethal gynecol. malignancy in the US, and angiogenesis is a particularly important target as VEGF levels are high, manifest as ascites and pleural effusions, and the response rates to single agent bevacizumab, a recombinant humanized monoclonal antibody directed against VEGF, are the highest (16-25%) of any reported in oncol. Antiangiogenics have generally been well tolerated, but are associated with gastrointestinal perforation in 1-2%. New angiogenesis targets are being identified (ANG-2, PDGFR, FGFR, inflammation and the microenvironment), and a plethora of new agents is in clin. development: tyrosine-kinase inhibitors (sunitinib, cediranib, pazopanib), multitargeted agents (XL-184), anti-angiopoietins (trebananib), novel antivascular approaches (VB-111 and ombrabulin). Antiangiogenic therapy appears to impact PFS, but does not impact cure. In subsets of patients, it may improve overall survival (OS), and its use remains costly and controversial. Although approved in Europe, the pathway to approval of bevacizumab for ovarian cancer in the US is currently still unclear. There is a clin. need to define the role of these drugs in ovarian cancer management and to identify robust predictive biomarkers. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Recommanded Product: 212141-54-3).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Recommanded Product: 212141-54-3

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Kang, Kyu-Tae et al. published their research in Yakhak Hoechi in 2018 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Pyridazine and phthalazine have quite different spectroscopic properties compared with their isomers, pyrazine and quinoxaline. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.Electric Literature of C20H15ClN4

Two-cell tube formation assay system for angiogenesis research was written by Kang, Kyu-Tae. And the article was included in Yakhak Hoechi in 2018.Electric Literature of C20H15ClN4 This article mentions the following:

Blood vessels are formed by two cell types: endothelial cells and vascular mural cells. However, most in vitro angiogenesis assays are performed by only endothelial cells. Here, we developed an in vitro angiogenesis assay system using two human vascular cell precursors: endothelial colony forming cells (ECFC) and mesenchymal stem cells (MSC). The progression of tube formation was monitored by a real-time cell recorder for 24 h. Utilized an image-stitching software to increase the analyzed image area up to 9-times larger than one image from 10X object lens. Tube number was higher in ECFC+MSC than ECFC at 6 h time point, but became lower at 12 and 24 h when compared with ECFC. The length per tube was higher in ECFC+MSC than ECFC at all-time points. VEGF treatment increased tube formation in both ECFC+MSC and ECFC. Vatalanib, VEGF inhibitor, inhibited tube formation of ECFC dose-dependently. Interestingly, ECFC+MSC-induced tube formation was not changed by vatalanib, suggesting that MSC may potentiate the stability and durability of tubular structures. These results indicate that two-cell tube formation assay system can mimic in vivo angiogenic process by two vascular cells, and will be an effective pre-clin. in vitro assay model to evaluate pro- or anti-angiogenic property. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Electric Literature of C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Pyridazine and phthalazine have quite different spectroscopic properties compared with their isomers, pyrazine and quinoxaline. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.Electric Literature of C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Latham, Antony M. et al. published their research in PLoS One in 2014 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine and phthalazinone derivatives are important owing to their significant biological activities and pharmacological properties. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Computed Properties of C20H15ClN4

In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis was written by Latham, Antony M.;Kankanala, Jayakanth;Fearnley, Gareth W.;Gage, Matthew C.;Kearney, Mark T.;Homer-Vanniasinkam, Shervanthi;Wheatcroft, Stephen B.;Fishwick, Colin W. G.;Ponnambalam, Sreenivasan. And the article was included in PLoS One in 2014.Computed Properties of C20H15ClN4 This article mentions the following:

Background: Protein kinases play a central role in tumor progression, regulating fundamental processes such as angiogenesis, proliferation and metastasis. Such enzymes are an increasingly important class of drug target with small mol. kinase inhibitors being a major focus in drug development. However, balancing drug specificity and efficacy is problematic with off-target effects and toxicity issues. Methodol.: We have utilized a rational in silico -based approach to demonstrate the design and study of a novel compound that acts as a dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1). This compound acts by simultaneously inhibiting pro-angiogenic signal transduction and cell cycle progression in primary endothelial cells. JK-31 displays potent in vitro activity against recombinant VEGFR2 and CDK1/cyclin B proteins comparable to previously characterized inhibitors. Dual inhibition of the vascular endothelial growth factor A (VEGF-A)-mediated signaling response and CDK1-mediated mitotic entry elicits anti-angiogenic activity both in an endothelial-fibroblast co-culture model and a murine ex vivo model of angiogenesis. Conclusions: We deduce that JK-31 reduces the growth of both human endothelial cells and human breast cancer cells in vitro . This novel synthetic mol. has broad implications for development of similar multi-kinase inhibitors with anti-angiogenic and anti-cancer properties. In silico design is an attractive and innovative method to aid such drug discovery. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Computed Properties of C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine and phthalazinone derivatives are important owing to their significant biological activities and pharmacological properties. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Computed Properties of C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Tenuta, Alessandro et al. published their research in BJU International in 2014 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Formula: C20H15ClN4

Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise was written by Tenuta, Alessandro;Klotz, Laurence;Parker, Jayson L.. And the article was included in BJU International in 2014.Formula: C20H15ClN4 This article mentions the following:

The objectives of the study were to determine the risk of failure during drug development in castration-resistant prostate cancer (CRPC) and to identify factors that could improve outcomes. We investigated CRPC by analyzing compounds in phase I to phase III clin. trials between 1998 and Apr. 2011. Drug development failures were classified as medical or com. and were compared with industry expectations. Compounds were excluded from anal. if their phase I occurred before 1998, if they targeted patients that were did not have hormone-refractory prostate cancer, or if they did not assess outcomes such as overall survival, time to disease progression, or prostate-specific antigen levels. Thorough searches of clinicaltrial.gov and other databases yielded 77 compounds that met the inclusion criteria. The cumulative pass rate for first-line compounds in CRPC was 3% and was far below aggregate industry expectations. In total, there were nearly equivalent numbers of com. and medical failures. Biol. products were found to have had greater relative success than small-mol. drugs and biotechnol. firms had been slightly more successful than pharmaceutical firms in this disease indication. Phase III failures were high, despite equally high failures during phase II. Currently, one in 33 compounds that enters clin. testing will be awarded US Food and Drug Administration approval. This appears to be the highest risk indication investigated to date, based on clin. trial studies alone, with an average cost of 1.411bn to bring a new drug to market when adjusted for risk. Development of radical therapeutics such as immunotherapies may also be warranted instead of classic antineoplastic therapeutics. Given the high clin. trial risk, efforts may have to shift to biomarker and surrogate endpoints to manage future clin. trial risk in prostate cancer. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Formula: C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazines, as an important class of bicyclic N-heterocycles, have attracted sizable attention due to their valuable biological and pharmacological activities. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Formula: C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Rosenthal, Arthur F. et al. published their research in Journal of Organic Chemistry in 1957 | CAS: 18393-54-9

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives.Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as analgesic, anticonvulsant, antitumor, antiproliferative. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.COA of Formula: C9H8N2O2

Cleavage of phthaloylglycine by substituted hydrazines was written by Rosenthal, Arthur F.. And the article was included in Journal of Organic Chemistry in 1957.COA of Formula: C9H8N2O2 This article mentions the following:

Refluxing 1.8 g. 2,5-dichlorophenylhydrazine, 1.03 g. phthaloylglycine (I), and 0.93 g. Bu3N in 5 cc. 95% EtOH 12 hrs. on a steam bath, adding 15 cc. Me2CO, refluxing the mixture another 15 min., evaporating the filtered solution in vacuo, taking up the residue in 15 cc. Et2O, treating the Et2O solution 1 min. with HCl, and evaporating the Et2O give 40% N-(2,5-dichlorophenyl)phthalhydrazide, faintly yellow crystals, m. 204-5°. Refluxing 1.03 g. I, 1.85 g. Bu3N, and MeNHNH2 from 1.44 g. sulfate 20 hrs. in 30 cc. 95% EtOH, evaporating the mixture to 1/3 its volume, adding 40 cc. EtCOMe, refluxing the mixture 15 min., filtering off 346 mg. glycine, evaporating the filtrate, and adding 40 cc. Et2O and 100 cc. C5H12 give 88% N-methylphthalhydrazide, m. 238.5-9.5° (N-acetyl-N’-methylphthalhydrazide, m. 139.5-40.5°). In the experiment, the researchers used many compounds, for example, 2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9COA of Formula: C9H8N2O2).

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives.Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as analgesic, anticonvulsant, antitumor, antiproliferative. In addition, phthalazines are known as serotonin reuptake inhibitors and are considered as anti-depression agents.COA of Formula: C9H8N2O2

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Arena, Claudia et al. published their research in BioMed Research International in 2018 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine and phthalazinone derivatives are important owing to their significant biological activities and pharmacological properties. As with pyridazines, phthalazines, the other benzopyridazines, were also prepared most frequently through the condensation of hydrazines with carbonyl-containing compounds, typically phthalate derivatives. COA of Formula: C20H15ClN4

Stomatitis and VEGFR-tyrosine kinase inhibitors (VR-TKIs): a review of current literature in 4369 patients was written by Arena, Claudia;Troiano, Giuseppe;De Lillo, Alfredo;Testa, Nunzio F.;Lo Muzio, Lorenzo. And the article was included in BioMed Research International in 2018.COA of Formula: C20H15ClN4 This article mentions the following:

Background. Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss of appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppression, and stomatitis. Materials and Methods. A systematic search was performed on PubMed online database using a combination of MESH terms and free text words, “sunitinib” OR “sorafenib” OR “axitinib” OR “cabozantinib” OR “pazopanib” OR “regorafenib” OR “nintedanib” OR “vatalanib” combined through the use of Boolean operator AND with the key words”stomatitis” OR “mucositis,” (i) on human subjects, (ii) written in the English language, and (iii) reporting about the incidence of stomatitis or oral mucositis. Results.. The incidence of stomatitis of any grade was 35.2% for sunitinib, 20.52% for sorafenib, 20.63% for axitinib, and 34.21% for cabozantinib. All the agents showed high rates of lowgrade stomatitis (G1-G2), while the onset of severe stomatitis (G3-G4) was very low. Conclusions. Anal. of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3COA of Formula: C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Phthalazine and phthalazinone derivatives are important owing to their significant biological activities and pharmacological properties. As with pyridazines, phthalazines, the other benzopyridazines, were also prepared most frequently through the condensation of hydrazines with carbonyl-containing compounds, typically phthalate derivatives. COA of Formula: C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Cheinker, Yu. N. et al. published their research in Journal de Chimie Physique et de Physico-Chimie Biologique in 1958 | CAS: 18393-54-9

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. New methods for the functionalization of pyridazine, phthalazine, and cinnoline rings emerged in 2016. Buchwald and his group devised an asymmetric hydroarylation of vinylarenes.Reference of 18393-54-9

Spectra and structure of derivatives of p-dihydroxypyridazine and phthalazine was written by Cheinker, Yu. N.;Gortinskaya, T. V.;Sycheva, T. P.. And the article was included in Journal de Chimie Physique et de Physico-Chimie Biologique in 1958.Reference of 18393-54-9 This article mentions the following:

IR and UV spectra of the dihydroxy derivatives of pyridazine and phthalazine, as well as their Me and Cl derivatives, were studied with a view to establishing the structure of the dihydroxy derivatives It was concluded that the compounds have mixed hydroxyoxo structures, both in the crystalline state and in solution Mols. of 3-hydroxy-6-pyridazine (I), as well as the 1-Me derivative, form chains in the crystalline state, in which each mol. is linked to 2 others by very stable H bonds. The H-bonds in 1-hydroxy-4-phthalazinone (II) do not lead to such chain formation in the crystalline state. The heats of fusion, solubility, and acidity of I, II, and derivatives are consistent with the proposed structures. IR spectra of the following compounds are given between 20 and 14 μ: 1,2-dimethyl-3,6-pyridazinedione, I, 3,6-dimethoxypyridazine, 1-methyl-3-methoxy-6-pyridazinone, 3-methoxy-6-pyridazinone, 1-methyl-3-hydroxy-6-pyridazinone, 2,3-dimethyl-1,4-phthalazinedione II, 1-methoxy-4-phthalazinone, 1-methoxy-4-chlorophthalazine, 3-chloro-6-pyridazinone, 3,6-dichloropyridazine, 3,6-bis(methylthio)pyridazine, 3-mercapto-6-thiopyridazinone, all in the crystalline state; also UV spectra in alc. In the experiment, the researchers used many compounds, for example, 2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9Reference of 18393-54-9).

2-Methyl-2,3-dihydrophthalazine-1,4-dione (cas: 18393-54-9) belongs to phthalazine derivatives. Phthalazine is isomeric with other naphthyridines including quinoxaline, cinnoline and quinazoline. New methods for the functionalization of pyridazine, phthalazine, and cinnoline rings emerged in 2016. Buchwald and his group devised an asymmetric hydroarylation of vinylarenes.Reference of 18393-54-9

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Li, Yan et al. published their research in Journal of Chemical Information and Modeling in 2016 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Although, N-containing heterocyclic compounds are widely distributed in nature, the presence of two adjacent nitrogen atoms in the phthalazine ring makes it rare and not very familiar in isolated extracts from living organisms. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Synthetic Route of C20H15ClN4

AutoT&T v.2: An Efficient and Versatile Tool for Lead Structure Generation and Optimization was written by Li, Yan;Zhao, Zhixiong;Liu, Zhihai;Su, Minyi;Wang, Renxiao. And the article was included in Journal of Chemical Information and Modeling in 2016.Synthetic Route of C20H15ClN4 This article mentions the following:

In structure-based drug design, automated de novo design methods are helpful tools for lead discovery as well as lead optimization. In a previous study the authors reported a new de novo design method, namely, Automatic Tailoring and Transplanting (AutoT&T). It overcomes some intrinsic problems in conventional fragment-based buildup methods. In this study, the authors describe an upgraded version, namely, AutoT&T2. Structural operations conducted by AutoT&T2 have been largely optimized by introducing several new algorithms. As a result, its overall speed in multiround optimization jobs has been improved by a few thousand fold. With this improvement, it is now practical to conduct structural crossover among multiple lead mols. using AutoT&T2. Three different test cases are described in this study that demonstrate the new features and versatile applications of AutoT&T2. The AutoT&T2 software suite is available to the public. Besides, a Web portal for running AutoT&T2 online is provided at http://www.sioc-ccbg.ac.cn/software/att2 for testing. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Synthetic Route of C20H15ClN4).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Although, N-containing heterocyclic compounds are widely distributed in nature, the presence of two adjacent nitrogen atoms in the phthalazine ring makes it rare and not very familiar in isolated extracts from living organisms. Phthalazine derivatives are also considered as p38MAP kinase inhibitors, selective binders of gamma-aminobutyric acid (GABA) receptors, cyclooxygenase-2 (COX-2) inhibitors, and high-affinity ligands of voltages gated calcium channels.Synthetic Route of C20H15ClN4

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem

Niimura, Takeshi et al. published their research in Bunshi Shokakibyo in 2012 | CAS: 212141-54-3

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as antimicrobial, antidiabetic, analgesic, anticonvulsant, antitumor, antiproliferative, antiepileptic, anti-inflammatory, and vasorelaxant. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Related Products of 212141-54-3

Possibility of new molecular-targeted therapy from the perspective of GIST treatment resistant examples was written by Niimura, Takeshi;Suzuki, Hiromu;Shinomura, Yasuhisa. And the article was included in Bunshi Shokakibyo in 2012.Related Products of 212141-54-3 This article mentions the following:

Imatinib mesilate (imatinib), sunitinib malate (sunitinib) are being used as a drug treatment against Gastrointestinal stromal tumor (GIST) but some cases having resistance against these drugs have also been appeared. Imatinib resistance includes a primary resistance wherein an effect is considered to be less from the beginning and a secondary resistance due to acquisition of new genetic mutation. The mechanism of sunitinib resistance is not completely understood; however, autonomous activation of KIT due to the mutation of activation loop and decrease in the development of PTEN due to the methylation of promoter area and activation of Akt path etc. have been reported. A medical treatment using multi-target Tyrosine kinase such as Nilotinib hydrochloride which is the new tyrosine kinase inhibitor against imatinib, sunitinib resistance cases, inhibitors of intracellular signal transmission path such a mTOR, sorafenib tosilate that targets both of the Tyrosine kinase and intracellular signal transmission mols. is being considered. In addition, the drugs targeting the mols. such as heat shock protein (Hsp) 90 which are involved in the tumor formation are being considered as medical treatment target and clin. trials are also in progress. In the experiment, the researchers used many compounds, for example, N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3Related Products of 212141-54-3).

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine (cas: 212141-54-3) belongs to phthalazine derivatives. Like many other isomeric benzodiazines, phthalazine derivatives reveal numerous pharmacological and biological activities such as antimicrobial, antidiabetic, analgesic, anticonvulsant, antitumor, antiproliferative, antiepileptic, anti-inflammatory, and vasorelaxant. Both pyridazine and phthalazine give rise to very good TREPR signals in rigid media at low temperatures.Related Products of 212141-54-3

Referemce:
Phthalazine – Wikipedia,
Phthalazine | C8H6N2 – PubChem